ArticleClinical, cosmetic and investigational dermatology2025
Successful Treatment with a Combination of Oral and Topical Glycyrrhizinic Acid in an Immunocompetent Anogenital Warts Patient.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Anogenital warts (AGW) are benign proliferative diseases caused by human papillomaviruses (HPV), characterized by verrucous papules on the genital or anal region In line with these findings, the prevalence of AGW is high among males and increasing in Indonesia, and most patients seek treatment because warts are cosmetically disfiguring and itchy. Self-applied treatments may cause local adverse effects such as irritation or burning. Oral and topical administration of glycyrrhizinic acid (Gly) has been observed to have antiviral and anticancer properties. Case Report: A 21-year-old immunocompetent patient presented with multiple verrucous lesions on the anal region. Histopathological results showed condyloma acuminate type of AGW, and polymerase chain reaction results showed HPV type 11. The patient was treated with a combination of 10 mL oral Gly thrice daily and self-applied topical Gly three to four pumps thrice daily. The lesions gradually resolved after the first week of the combination of treatments. Subsequently, after 12 weeks of treatment, the wart decreased to one verrucous lesion, and the patient showed no adverse effects. Discussion: Gly exhibited broad-spectrum antiviral effects against HPV, herpesviruses, hepatitis viruses, and others. Oral and topical applications are considered safer than intravenous administration. Previous studies on Gly-based topical treatment showed effectiveness in the treatment of AGW with minimal side effects. Oral Gly supplements also have been found to enhance immune response and aid in HPV treatment, particularly when combined with topical Gly. According to the results, a combination of oral and topical Gly leads to high HPV clearance rates, making it a promising non-invasive treatment option. Conclusion: The combination of topical and oral Gly appears to be a promising self-applied treatment of AGW. However, the potential for recurrence warrants further observation and long-term follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.